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Transient receptor potential vanilloid type channels (TRPVs) are expressed in several cell types in human and animal lungs. Increasing
evidence has demonstrated important roles of these cation channels, particularly TRPV1 and TRPV4, in the regulation of airway function. These
TRPVs can be activated by a number of endogenous substances (hydrogen ion, certain lipoxygenase products, etc.) and changes in physiological
conditions (e.g., temperature, osmolarity, etc.). Activation of these channels can evoke Ca2+ influx and excitation of the neuron. TRPV1 channels
are generally expressed in non-myelinated afferents innervating the airways and lungs, which also contain sensory neuropeptides such as
tachykinins. Upon stimulation, these sensory nerves elicit centrally-mediated reflex responses as well as local release of tachykinins, and result in
cough, airway irritation, reflex bronchoconstriction and neurogenic inflammation in the airways. Recent studies clearly demonstrated that the
excitability of TRPV1 channels is up-regulated by certain autacoids (e.g., prostaglandin E2, bradykinin) released during airway inflammatory
reaction. Under these conditions, the TRPV1 can be activated by a slight increase in airway temperature or tissue acidity. Indirect evidence also
suggests that TRPV channels may play a part in the pathogenesis of certain respiratory diseases such as asthma and chronic cough. Therefore, the
potential use of TRPV antagonists as a novel therapy for these diseases certainly merits further investigation.
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Transient receptor potential (TRP) ion channel family consists
of 28 ion channels, and can be further divided into six subgroups
based upon the structure and activation characteristics of the
channels [1,2]. TRP subfamilies include canonical (TRPC, 7
channels), melastatin (TRPM, 8 channels), ankyrin (TRPA, 1
channel), vanilloid (TRPV, 6 channels), polycystin (TRPP, 3
channels) and mucolipin (PRTML, 3 channels) families. TRPV
channel family (TRPV1–6) are widely expressed in various cell
types of the mammalian organ systems. Since these TRPV
channels were cloned in the last several years, increasing
evidences begin to reveal the important physiological properties
and function of these channels. TRPV channels are nonselective
cation channel with a high permeability to Ca2+, and the
selectivity of cations varies among different TRPV channels. It
is well recognized that intracellular calcium is an important signal⁎ Corresponding author. Tel.: +1 859 323 6339; fax: +1 859 323 1070.
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doi:10.1016/j.bbadis.2007.01.013transduction molecule in all cells, and plays a critical role in the
regulation of membrane excitability, neurotransmitter release,
synaptic transmission and other important biological functions in
neurons. Hence, because of the high permeability to Ca2+ and
their sensitivities to various physiological stimuli, TRPV channels
are believed to play an important role in the regulation of airway
function under both normal and disease conditions.
Ion channels in TRPV family can be activated by a diverse
range of biological stimuli that are found in the respiratory tract,
including acid, changes in temperature and osmolarity,
mechanical stress, change in intracellular Ca2+ concentration,
and various inflammatory mediators. In addition, up-regulation
of TRPV expression and sensitivity in the lung may also
contribute to the manifestation of various symptoms of airway
inflammatory diseases. In this review, we discuss the expression
and function of TRPV channels in the lung, the endogenous
substances and physiological conditions that can activate and
modulate the sensitivity of these channels, and the potential
involvements of TRPVs in the pathogenesis of certain
respiratory diseases.
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Several TRPV channels have been detected in mammalian
lung tissues, including airway sensory nerves, airway smooth
muscle cells, epithelial cells, vascular endothelial cells,
submucosal glands, and inflammatory cells [3–7]. Although
their precise roles in regulating the function of each
individual cell type are not clearly defined, recent studies
have revealed some convincing evidence of their involve-
ments under both normal and disease conditions. Of course,
many of these studies were performed in the heterologously
expressed TRPV channels, cautions are required in extra-
polating these findings to the responses in native cells and
biological systems, and certain inherent limitations should
also be taken into consideration in predicting the potential
physiological implications. We will focus this review
primarily on the function of TRPV1 and TRPV4 expressed
in the respiratory tract because of the recent progresses in
research on these two TRPV channels and our existing
knowledge about their possible involvements in the patho-
genesis of certain airway diseases.
2.1. TRPV1
2.1.1. TRPV1 expression in the airway
The expression of the TRPV1 in the mammalian respiratory
tract is predominantly localized in the sensory nerves, despite
that its presence in other cell types has also been reported. The
afferent activities arising from sensory terminals located in the
lung and airways are conducted primarily by branches of vagus
nerves [8,9] that project to the nucleus tractus solitarius in the
brainstem, and their cell bodies reside in the nodose and
intracranial jugular ganglia. Among these vagal bronchopul-
monary afferents, approximately 75% are small-diameter, slow-
conducting non-myelinated (C-) fibers [10]. One of the most
distinct characteristics of these C-fiber afferents is the functional
expression of TRPV1 at the sensory terminals, as evident by
their exquisite sensitivity to capsaicin delivered either by
inhalation or by injection into the pulmonary circulation
[11,12]. In a sharp contrast, their myelinated counterpart of the
vagal pulmonary afferents either do not or rarely exhibit any
sensitivity to capsaicin [11].
Immunohistochemical evidence shows that TRPV1 channels
are often co-localized with certain sensory neuropeptides, such
as tachykinins (TKs) and calcitonin gene-related peptide
(CGRP), in the same axon [7,13,14]. These TRPV1-expressing
C-fiber endings also display distinct sensitivity to chemical
irritants as well as certain endogenously released autacoids
[11,12,15,16]. Recent studies suggest that the actions of some of
these stimulants are mediated through the activation of TRPV1.
These chemosensitive endings innervate the entire respiratory
tract, from upper airways (nose, larynx, trachea) to lung
parenchyma (alveolar wall). They are found in the mucosa as
well as in the deeper regions of the airway structure (e.g., near
smooth muscles). In the conducting airways, they show
extensive axonal arborization that either extends into the space
between epithelial cells or forms network-like plexus immedi-ately beneath the basement membrane of airway epithelium in
various species including humans [17–19].
2.1.2. Biological response to TRPV1 activation
Activation of TRPV1 channels on airway sensory nerves
induces Ca2+ influx into the neuronal cell, membrane depolariza-
tion and action potentials. Activation of these TRPV1-expressing
vagal sensory terminals in the airways can elicit extensive reflex
responses such as bronchoconstriction, mucus secretion, brady-
cardia and hypotensionmediated through the efferent pathways of
the autonomic nervous system, which are accompanied by rapid
shallow breathing, airway irritation and cough. Together, these are
the typical respiratory defense responses against inhaled irritants
[12,20]. Ca2+ influx evoked by TRPV1 activation can also trigger
the release of TKs and CGRP from both peripheral and central
nerve terminals. These neuropeptides are known to act on a
number of effector cells in the respiratory tract (e.g., airway and
vascular smoothmuscles, cholinergic ganglia, inflammatory cells,
mucous glands), and cause bronchoconstriction, protein extra-
vasation, airway mucosal edema and inflammatory cell chemo-
taxis [21,22]. Thus, prolonged and intense stimulation of these
endings can lead to the development of “neurogenic inflammatory
reaction” in the airways [21,23,24].
2.2. TRPV4
2.2.1. TRPV4 expression in the lung
The TRPV4 channel is widely expressed in mammalian
tissues including lung, heart, kidney, sensory neurons, sympa-
thetic nerves, brain, skin, intestine, salivary glad, sweat glands,
inner ear, endothelium and fat tissue [25–30]. In the lung,
TRPV4 is detected by RT-PCR in a human bronchial epithelial
cell line [31] and in cultured human airway smooth muscle cells
[32]. Immunohistochemistry study showed that TRPV4 is
expressed in the alveolar wall in human, rat andmouse lung [33].
2.2.2. Biological response to TRPV4 activation
Activation of TRPV4 channel increases intracellular Ca2+
concentration and thus may play an important role in Ca2+
signaling during osmotic stimulation. The physiological role of
TRPV4 activation may vary among different tissues. TRPV4 in
human bronchial epithelial cells may be involved in hypotonic
solution-induced cell regulatory volume-decrease response
through the activation of Maxi K+ channels [31]. TRPV4
activation also induces Ca2+ influx in human airway smooth
muscle cells as well as smooth muscle contraction in isolated
human and guinea pig airways [32]. In isolated rat lung, TRPV4
activation increases endothelial permeability and disrupts the
alveolar septal barrier [33].
3. Endogenous TRPV activators and modulators in normal
and disease conditions
3.1. Endogenous activators of TRPV1
Recent studies have demonstrated several endogenous
chemical substances that can activate TRPV1 in the lung, and
Fig. 1. Role of TRPV1 in the acid-evoked currents in rat vagal pulmonary
sensory neurons. Panel A: representative records illustrating the effects of
amiloride (100 μM; 2 min) and capsazepine (CPZ; 10 μM, 2 min) on pH 5.5
(6 s)-evoked inward currents in a jugular neuron (23.1 pF). Panel B: group data
showing the effects of 2-min pretreatment with amiloride (100 μM) and CPZ
(10 μM) on both transient and sustained components evoked by low pH
(6.5−5.5; 6 s). *P<0.05 as compared with the corresponding control. Data
represent means±SEM (from Ref. [44]).
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various pathophysiological conditions in the airways.
3.1.1. Hydrogen Ion
Inhalation of acidic aerosol or right-atrial injection of lactic
acid elicits cough and reflex bronchoconstriction in humans
and animals [34–36], suggesting that stimulation of lung
afferents is involved [37,38]. It is known that hydrogen ion
can modulate the stimulatory effect of capsaicin on hetero-
logously expressed TRPV1 [39]. The sites of interaction have
been suggested to be located within putative extracellular
loops of TRPV1, particularly at two glutamate residuals E648
and E600 [40]. The evidence of acid stimulation of TRPV1 in
the airway nerves was first reported by Fox and co-workers
[41] who demonstrated that C-fiber afferents innervating the
guinea pig trachea were stimulated when the isolated guinea
pig airway was perfused with acidic buffer at pH of 5.0, and
that the effect was abrogated by capsazepine [42]. However, it
is also possible that certain autacoids (e.g., lipooxygenase
metabolites, etc.) are released from the surrounding tissue
upon the action of hydrogen ion, which in turn can activate the
TRPV1 receptor on the nerve terminals [43]. A direct
stimulatory effect of hydrogen ions on TRPV1s was recently
demonstrated in pulmonary sensory neurons isolated from rat
nodose/jugular ganglia [44]. The current evoked by lowering
the pH of extracellular solution to 7.0 consisted of only a
transient, rapidly inactivating component with small ampli-
tude, which increased in amplitude when the H+ concentration
was elevated. In addition, a slow, sustained inward current
began to emerge when pH was reduced to below 6.5. The
transient component was dose-dependently inhibited by amilor-
ide, a common blocker of acid-sensing ion channels (ASICs)
[45], whereas the sustained component was almost completely
abolished by capsazepine, indicating a critical involvement of
TRPV1 in the acid-evoked current in these neurons (Fig. 1) [44].
Presumably, this long-lasting effect of TRPV1-activation is
responsible for, to some extent, the lingering irritant effect of
acid on the airways.
3.1.2. Lipoxygenase products of arachidonic acid
Products derived from lipoxygenase metabolism of arachi-
donic acid are released in inflammatory tissues, and are believed
to be involved in the inflammation-induced hyperalgesia [46].
Some of these lipoxygenase products, such as 12-(S)- and
15-(S)-hydroperoxyeicosatetraenoic acid (12S- and 15S-
HPETE), have been shown to exert a highly potent stimulatory
effect on TRPV1 [43], and several isoforms have been found in
the lung tissue [47–49]. These lipoxygenase products are
known to be released in the airways during asthmatic attack
[50], and therefore are considered as the primary candidates of
the endogenous TRPV1 activators in airway inflammatory
diseases. However, despite all the suggestive evidence, the
convincing in-vivo or in-vitro evidence demonstrating the direct
activation of TRPV1-expressing sensory nerves in the airways
is still lacking; this discrepancy may be related to the
instability of these compounds and the difficulty of effectively
delivering them to the receptor site. This notion is supportedby the findings that endogenously released lipoxygenase
products are critically involved as the intermediate mediators in
the activation of TRPV1 by certain autacoids (e.g., bradykinin)
[51–53].
3.1.3. Anandamide
Anandamide, an endogenous neuronal lipid mediator, is
the ethanolamine amide of arachidonic acid first isolated from
porcine brain [54]. Anandamide is synthesized in the nervous
system as well as in peripheral tissues including airways and
lung [55,56]. Anandamide is previously known as a
cannabinoid receptor agonist. Recent evidence shows that
anandamide also activates human and rat TRPV1 receptors in
TRPV1-transfected cells, rat dorsal root ganglia (DRG)
neurons in vitro [57,58], and bronchopulmonary C-fiber
afferents in vivo [59–61]. Anandamide has a similar Ki for
TRPV1 in recombinant cell lines, but a distinctly lower
potency in various assays [62], which raises the question as to
the probability of its action as an endogenous activator of
TRPV1 [61]. Anandamide is found to be either a partial or a
full agonist depending on the tissue tested as well as the
physiological conditions. For example, as a partial agonist,
anandamide may sensitize the channel response to other
TRPV1 agonists, while in certain pathophysiological condi-
tions (e.g., airway inflammation) when TRPV1 sensitivity is up-
regulated, anandamide may serve as an endogenous agonist and
activate the channel. A recent study further revealed the role of
anandamide as an intracellular messenger that is formed
following the activation of phospholipase C/inositol 1,4,5-
triphosphate pathway and can activate the TRPV1 in rat DRG
neurons [62].
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TRPV1 is generally considered as the sensor for detecting
noxious heat in the somatic sensory system, and its response
characteristics and channel activation by heat are well
documented [63,64]. Because the temperature threshold for its
activation is relatively high (43 °C) and the pulmonary sensory
nerves is constantly exposed to body temperature, a possible
role of the TRPV1 as a thermal sensor in the physiological range
of body temperature was generally overlooked. However, a
recent study showed that increasing temperature from 23 °C to
41 °C in a ramp pattern evoked an inward current or membrane
depolarization in isolated rat pulmonary sensory neurons after
exceeding a threshold of ∼34.4 °C. Further increase in tempe-
rature increased the amplitude of inward current sharply, or
evoked action potential as the temperature reached 39–40 °C.
The temperature coefficient, Q10, was 29.5±6.4 over the range
of 35–41 °C and distinctly higher than that over the lower
temperature range (23–30 °C, Q10=2.84±0.56), which clearly
illustrates the thermal sensitivity of these pulmonary sensory
neurons [4]. Approximately 48% of the response was blocked
by pretreatment with capsazepine, suggesting an important role
of the TRPV1; the remaining response probably involves
TRPV2–4 channels because it was totally abolished by
ruthenium red, a non-selective TRPV and calcium channel
blocker (Fig. 2) [4]. In view of the facts that hyperthermiaFig. 2. Involvements of TRPV1 and other TRPVs in the responses of isolated rat va
clamp mode, increasing the temperature in a ramp pattern evoked depolarization an
display the action potential signals at an expanded time scale. Panel B: in voltage-c
hyperthermia were applied to a jugular neuron (28.6 pF). Panel C: the consistent temp
same neuron (from data shown in Panel B). TI20% was determined by locating the tem
generated at 41 °C. Panel D: representative traces illustrating the inward currents e
10 μM), a selective TRPV1 antagonist, and ruthenium red (RR, 3 μM), a non-selec
neuron (28.6 pF). At least 10 min was allowed for the cell to recover between tests. P
Panel D. Panel F: group data showing the effects of different treatments on cell respo
these cells). *, significantly different (P<0.05) from the control response; †, signif
(modified from Ref. [4]).occurs commonly in normal (e.g., during exercise) as well as in
disease conditions (e.g., fever, heat stroke) and that a
significantly higher tissue temp was found in the airways of
asthmatic patients [65], the thermal sensitivity of individual
TRPV channels and their relative contributions to the regulation
of airway function certainly require further investigation.
3.1.5. Other endogenous TRPV1 activators
Based upon the structure–activity relationship studies,
several endogenous agonists of TRPV1 have been proposed.
N-arachidonoyl-dopamine (NADA) is an endogenous sub-
stance with structural similarity to capsaicin and has been
found in mammalian nervous tissues, mostly in the central
nervous system. NADA activates the TRPV1 over-expressed
in HEK293 cells, with potency and efficacy similar to those
of capsaicin. Furthermore, NADA can activate TRPV1
channels in the nociceptive neurons in rat dorsal root ganglion
[66]. Similarly, N-oleoyldopamine (OLDA) was found in
mammalian brain, and can activate the TRPV1-transfected
HEK cells in vitro and induce a hyperalgesic effect in vivo [67],
which can be blocked by iodo-resiniferatoxin, a TRPV1
antagonist. To our knowledge, the physiological and pharma-
cological actions of these compounds on capsaicin-sensitive
afferents innervating the airways and lung have not been
studied.gal pulmonary sensory neurons to increase in temperature. Panel A: in current-
d action potentials in a jugular neuron (21.0 pF). V, membrane potential. Insets
lamp mode (holding potential=−70 mV), capsaicin (0.5 μM, 2-s duration) and
erature–current relationships of the two different hyperthermia challenges in the
perature point where the amplitude of the current reached 20% of the peak current
voked by hyperthermia at control, after pretreatments with capsazepine (CPZ,
tive but effective blocker of TRPV1–4 channels, and after washout in a jugular
anel E: the temperature–current relationships of the four current traces shown in
nse to hyperthermia. Data are means±SEM (n=11; RR was studied in only 9 of
icant difference (P<0.05) between the responses after CPZ and RR treatments
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extracellular concentrations of cations, such as Na+, Mg2+, and
Ca2+, can actively gate the TRPV1 channel expressed in
HEK293 cells and oocytes, and these effects seem to result form
electrostatic interactions between these ions and two glutamates
located near the channel pore (E600 and E648), formerly
identified as proton-binding residues [40,68]. In addition,
polyamines, such as spermine and putrescine, which are
positively charged can directly activate TRPV1 in a charge-
dependent manner, both in heterologous expression systems and
in sensory neurons [69]. These observations are consistent with
the finding that eosinophil granule-derived proteins carrying
cationic charges can activate and sensitize the TRPV1-
expressing pulmonary sensory nerves in anesthetized rats
[70,71].
Reactive Oxygen Species (ROS) such as hydrogen peroxide
and hydroxyl radicals have been suggested to play a part in the
nociceptor activation during tissue inflammation and ischemia
[72], but transduction mechanism was not fully understood.
Recent studies have revealed that activation of the TRPV1
receptor by cyclooxygenase metabolites is partially responsible
for ROS-evoked stimulation of pulmonary C-fiber afferents in
rats because the stimulatory effect of aerosolized hydrogen
peroxide was reduced to half by pretreatment with either
capsazepine or indomethacin [73,74].
Although most of the TRPV channels are considered to be
voltage independent, a recent study has clearly shown that
physiological stimuli of TRPV1 (and some other temperature-
sensitive TRP channels), such as high temperature and
capsaicin, can shift its activation curve (open probability vs.
voltage) from a non-physiological positive voltage range
towards the negative potential [75]. This large shift of
voltage-dependent activation curve to a physiologically relevant
voltage range with a relatively small gating charge is believed to
be an important factor underlying the functional properties of
TRPV1 and its sensitivity to a diverse range of biological
stimuli [75].
3.2. Endogenous TRPV4 activators
Heterologously expressed TRPV4 channel can be activated
by hypotonic solutions [27], phorbol derivatives [76,77] and by
increase in temperature [25,78]. It has been reported that the
osmolarity of airway surface fluid is about 80% of isotonic body
fluids (222 vs. 285 mOsM) in healthy humans [79]. However,
the osmolarity of airway surface fluid is significantly decreased
in certain airway diseases (e.g., asthma; [79]). Hypotonicity has
also been reported in rat and mouse airway surface fluid [80,81].
This level of hypotonicity is likely to be sufficient to activate
TRPV4 if airway smooth muscle cells are exposed in situ. In
normal airways, TRPV4 on smooth muscle cells may not be
activated by the hypotonic airway surface fluid because of the
epithelium barrier. However, when the epithelium is disrupted
in inflammatory airway diseases such as asthma [82,83], airway
smooth muscles are exposed to the hypotonic airway surface
fluid, which may then activate the TRPV4 on these muscle
cells. Indeed, inhalation of distilled water or hypotonic salineaerosols induces bronchoconstriction and a fall in forced
expiratory volume in one second (FEV1) in asthma patients
but not in normal subjects [84–88]. Part of the bronchoconstric-
tion is probably mediated through cholinergic reflex since
hypotonicity can stimulate both C-fiber afferents and rapidly
adapting receptors in the airways, although a lack of chloride
ion appears to be also a contributing factor [89–91]. TRPV4
activation also increases the permeability of endothelial cells
and disrupts the alveolar septal barrier in isolated rat lung.
Therefore, it has been suggested that the TRPV4 activation may
be involved in the development of acute lung injury [33].
TRPV4 can be also activated by increase in temperature with
an activation threshold of 24° −32 °C [2,25,78,92], which is
below the normal range of body temperature. Thus, whether the
thermal sensitivity of TRPV4 plays any role in the regulation of
physiological function of lung afferents remains to be
determined, despite that both mRNA and protein expression
of TRPV4 have been demonstrated in the pulmonary sensory
neurons [4].
3.3. Endogenous modulators of TRPV sensitivity
It is well documented that a number of endogenous
inflammatory mediators can modulate the sensitivity of
TRPV1 during tissue inflammation, which leads to nociceptor
hypersensitivity and hyperalgesia. The mechanisms underlying
the sensitization of TRPV1 are not yet fully understood, but
several signal transduction pathways are known to be involved;
TRPV1 has several consensus phosphorylation sites that can be
phosphorylated by protein kinases A, C, and G (PKA, C and G),
tyrosine kinase, etc. [93–96]. As demonstrated in recent studies,
some of the endogenous mediators can modulate the excitability
of TRPV1 expressed in pulmonary/airway sensory neurons and
enhance the airway responsiveness to chemical irritants.
3.3.1. Prostaglandin E2
The sensitivity of cough reflex elicited by capsaicin is
enhanced by inhaled PGE2 in healthy human volunteers [97],
suggesting a PGE2-induced sensitization of TRPV1 in pulmon-
ary sensory nerves. Indeed, this contention is supported by the
observation that exogenous PGE2 at a low dose markedly
enhances the excitabilities of vagal pulmonary C-fibers to
capsaicin in anesthetized rats [98]. In cultured nodose and
jugular pulmonary sensory neurons, PGE2 (1 μM) markedly
increased the whole cell current density and the number of
action potentials evoked by capsaicin [94]. The sensitizing
effect of PGE2 could also be mimicked by butaprost [94], a
selective agonist of the EP2 prostanoid receptor, or by a direct
activation of adenylyl cyclase or protein kinase A (PKA), and
prevented by pretreatment with inhibitors of adenylyl cyclase or
PKA [93]. Taken together, these studies suggest that PGE2
activates the Gs protein-coupled EP2 prostanoid receptor present
on the membrane of these neurons, which upon activation
increases the enzyme activity of adenylyl cyclase [93,94,99].
The resulting rise in cAMP may then stimulate PKA, which in
turn increases the phosphorylation of TRPV1 and enhances its
excitability [94,100].
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Bradykinin, a nonapeptide derived from kininogen precur-
sors, is produced upon the activation of tissue or plasma
kallikreins by tissue damage, viral infection and other
inflammatory reactions. A pronounced increase in kinin and
kallilrein activity in the bronchoalveolar lavage was found in
patients suffering from asthma attack or anaphylaxis [101].
Bradykinin has been shown to enhance the sensitivity of C-fiber
afferents to capsaicin in isolated guinea pig airways [102].
Although the mechanisms underlying this action are still not
fully understood, activation of the G protein-coupled bradykinin
B2 receptors is believed to play a part in this action. An
involvement of TRPV1 channel in the bradykinin-induced
increase in the excitability of these sensory neurons has been
reported in several recent studies [60,95,103]. One possibility is
that modulation of the TRPV1 current by bradykinin is
generated by a direct action of PKC on the TRPV1 receptor
[95]. A recent study by Carr et al. [51] further revealed that B2
receptor-mediated effect of bradykinin on airway C-fibers is
mediated through the production of lipooxygenase products that
in turn activate TRPV1 receptors. This possibility is supported
by the finding that bradykinin induces the production of 12-
lipoxygenase metabolites of arachidonic acid in DRG neurons
[53]. Furthermore, activation of the B2 receptor is known to
stimulate phospholipase C and increase production of diacyl-
glycerol (DAG), which in turn activates the protein kinase C
(PKC) [103]; pretreatment with the B2-receptor antagonist or
the PKC inhibitor effectively attenuates the effect of bradykinin
on these nociceptive afferents [104–106]. In isolated guinea pig
trachea-bronchus preparation, bradykinin has been shown to
activate airway C-fiber afferents through a combined effect of
activation of both TRPV1 and Ca2+-activated chloride channels
[107].
3.3.3. Nerve Growth Factor (NGF)
NGF is a member of neurotrophin family, and known for its
important influence on the growth and maintenance of certain
specific subsets of peripheral sensory neurons [108]. Recent
investigations have further revealed its important role as an
inflammatory mediator during acute tissue injury; in patients
with asthma or other types of airway inflammatory reactions,
there is a pronounced increase in the NGF level in the serum and
bronchoalveolar lavage fluid [109,110]. Administration of NGF
in somatic tissues induces both acute and long-lasting
hyperalgesic effects, and increases the capsaicin sensitivity in
DRG nociceptive neurons [111]. In cultured DRG neurons or
frog oocytes co-expressing TRPV1 and TrkA tyrosine kinase
receptors, NGF increases the neuronal sensitivity to capsaicin,
hydrogen ion and thermal stimulation [103,111]; the responses
to these stimuli seem to be linked specifically to a modulatory
effect on the TRPV1 [103]. Whether NGF also alters the
excitability of other ligand-gated channels in nociceptive
neurons is unclear [112]. This hyperalgesic action of NGF on
DRG neurons is believed to be mediated through the G-protein-
coupled TrkA receptors, which in turn activates mitogen-
activated protein kinase and phospholipase C (PLC)-γ signaling
pathway [103,113]. Furthermore, these studies suggest that PLCactivation is the primary pathway in the NGF-induced
potentiation of TRPV1 channel [103]. A recent study further
demonstrated that phosphoinositide 3-kinase (PI3K) is physi-
cally and functionally coupled to TRPV1, which facilitates
trafficking of TRPV1 to the plasma membrane [114]. More
interestingly, the NGF-induced sensitization of DRG neurons
can be completely abrogated by inhibition of PI3K activity
[114].
3.3.4. Hydrogen ion
It is well documented that pH is reduced in the extracellular
fluid of inflamed and ischemic tissues. In patients during
asthmatic attack, the pH in the expired breath condensate is
reduced to 5.23, as compared to 7.65 in healthy subjects. This
abnormally low airway pH returns to normal after anti-
inflammatory therapy, suggesting that the airway acidosis is
caused by tissue inflammation [115,116]. Tissue acidification
has been shown to induce hyperalgesia by sensitizing
nociceptors in the somatic afferents [117,118]. Electrophysio-
logical recording further demonstrated that acid enhanced the
stimulatory effect of capsaicin on DRG neurons and hetero-
logously expressed TRPV1, indicating a positive interaction
between H+ and TRPV1 [39,118,119]. Acidification of lung
tissue occurs commonly when CO2 concentration increases in
the alveolar gas, resulting from exceedingly high CO2
production (e.g., during strenuous exercise) and/or from
hindered CO2 elimination from the lungs (e.g., in obstructive
airway diseases). A recent study showed that the stimulatory
effect of capsaicin on pulmonary C-fiber afferents was
markedly elevated, when pH in the pulmonary venous (left
atrial) blood was reduced from 7.40 to 7.17 during alveolar
hypercapnia [120]. The hypersensitivity of TRPV1 could be
largely prevented by infusion of bicarbonate to minimize the
change in blood pH, further demonstrating the modulatory
effect of H+ on TRPV1 sensitivity.
3.3.5. Proteases
Proteases such as trypsin and elastase are released from mast
cells and leukocytes during tissue inflammation and injury, and
can cleave protease-activated receptor 2 (PAR2) expressed on
primary afferent neurons to cause neurogenic inflammation and
hyperalgesia in somatic tissue. The PAR2-induced hyperalgesic
effect involves sensitization of TRPV1, and can be abrogated by
antagonist of PAR2, PKC or TRPV1 [121,122]. In DRG
neurons, stimulation of PAR2 activates PKCε and PKA, which
in turn increases the TRPV1 excitability [123]. A recent study
showed that activation of PAR2 up-regulates the excitability of
isolated rat pulmonary chemosensitive neurons, and the effect
of PAR2 activation was mediated though the PLC/PKC
transduction pathway [44]. These results suggest that the
interactions between PAR2 and pulmonary sensory nerves may
play a part in the airway hyperresponsiveness induced by PAR2
activation. Indeed, it has been reported that PAR2 activation
increases the TRPV1-mediated cough in guinea pigs via
activation of PKC- and PKA-signal transduction pathways as
well as the endogenous release of prostanoids [124]. A recent
report further demonstrated that PAR2 cleavage by proteases
Fig. 3. Immunofluorescence staining of airway nerves in a bronchial biopsy with
an anti-TRPV1 antibody in a normal non-coughing volunteer (norm; Panel 1)
and in a patient with chronic cough (cough; Panel 2). Panel 3 shows no staining
with the negative control when the primary antibody was not added. Individual
percentages of bronchial epithelial area stained positive for TRPV-1 was
significantly greater in patients with chronic cough than in healthy volunteers
(P<0.001; Panel 4). Arrows denote positive neuronal staining; original
magnification x250. There was a significant correlation (r=−0.41; P<0.05)
between TRPV-1 expression (percentage of epithelial area) and the capsaicin
concentration PC5 in the 29 patients with chronic cough (Panel 5); PC5 is the
concentration (μM) of capsaicin aerosol that evoked five coughs or more in
individual patients (modified from Ref. [131]).
921Y. Jia, L.-Y. Lee / Biochimica et Biophysica Acta 1772 (2007) 915–927activates a second messenger to increase the sensitivity of the
TRPV4 naturally expressed in the bronchial epithelial cells and
induce mechanical hyperalgesia in mice [125].
4. Potential role of TRPV channels in respiratory
diseases
4.1. Cough
Cough is arguably the most common symptom associated
with pulmonary diseases, such as bronchitis, COPD and the
common cold. This respiratory defense mechanism is facilitated
by a coordinated effort of neuromuscular elements that
comprises a complex reflex arc. The reflex arc includes a
vagal sensory afferent limb, a central processing center locate in
the lower brainstem referred to as the “cough center” and an
efferent motor limb. Increasing evidence has suggested a
significant role of TRPV1 in the genesis of cough, as evidenced
by the following observations. Firstly, it is generally believed
that the airway sensory nerves expressing TPRV1 receptors are
involved in eliciting the cough reflexes [100,126]. Inhalation of
capsaicin or acid aerosol consistently and reproducibly
produces coughs in a dose-dependent manner in humans and
various animals [34,127–129], and both these tussive agents
commonly used in human studies are potent TRPV1 activators.
Secondly, a number of endogenous inflammatory mediators that
are known to upregulate the TRPV1 sensitivity, such as PGE2,
bradykinin, histamine, etc., can also enhance the cough
sensitivity in experimental animals as well as in human subjects
[97,102,130]. Thirdly, over-expression of TRPV1 is found in
the bronchial tissue of patients with chronic cough [131,132];
when the airway mucosal biopsies were obtained by fiberoptic
bronchoscopy and compared between healthy volunteers
(n=17) and patients with chronic cough (n=29), a five-fold
increase of TRPV-1 immunoreactive nerve profiles was found
in patients with cough [131] (Fig. 3). Furthermore, there was a
significant correlation between the cough sensitivity to
capsaicin inhalation challenge and the density of TRPV1-
expressing nerves in the mucosa of patients with cough (Fig. 3).
These findings offer compelling evidence to suggest that an
increase in expression and/or sensitivity of TRPV1 in the
sensory endings of airway mucosa may be involved in the
development of chronic cough.
4.2. Asthma
Asthma is a chronic inflammatory disease characterized by
reversible airway obstruction and bronchial hyperresponsive-
ness to various stimuli, and indirect evidences have suggested a
potential involvement of TRP channels in the pathogenesis of
asthma. For example, it is known that TRPC6 is expressed in
eosinophils, neutrophils, mast cells and CD4+ T-lymphocytes,
the major immune cells involved in the pathogenesis of asthma
and airway allergic reaction [133–135]. In addition, expression
of TRPV1 in airway C-fiber sensory nerves is well documen-
ted, and activation of these sensory nerves by endogenous
TRPV1 activators or inhaled irritants and the resulting releaseof tachykinins are believed to contribute to the manifestation of
various pathophysiological features of asthma. Endogenous
TRPV1 activators, such as airway acidification and lipoxy-
genase products, have been detected in asthmatic patients
[50,115]. Inhaled capsaicin induces bronchoconstriction in
40% of asthma patients but not in normal subjects [136].
Capsaicin-induced cough response is increased in asthmatic
patients, indicating an increased TRPV1 activity in asthma. In
allergic animal models, pre-treatment with capsaicin to
degenerate the airway TRPV1-expressing afferents and to
deplete sensory neuropeptides, inhibits allergen-induced airway
constriction in sensitized guinea pigs [137] and airway
hyperresponsiveness in allergic rabbits [138], suggesting an
important role of these airway sensory nerves. In a mouse
model of non-atopic asthma, dinitrofluirobenzene sensitization
and challenge induces inflammatory cells accumulation and
airway hyperresponsiveness; these responses can also be
inhibited by capsaicin pretreatment [139]. Recent studies
have further presented convincing evidence of an important
role of TRPV1 in the manifestation of various symptoms of
airway hypersensitivity associated with airway inflammation
[16,32,140]; for example, bronchomotor response and cough
sensitivity to TRPV1 activators, capsaicin or citric acid aerosol,
922 Y. Jia, L.-Y. Lee / Biochimica et Biophysica Acta 1772 (2007) 915–927are markedly elevated in patients with asthma or airway
inflammation [141,142]. One of the most prominent patho-
physiological features of asthma is bronchial hyperresponsive-
ness [143,144], which is generally believed to be closely
associated with endogenous release of various chemical
mediators from inflammatory cells. Recent studies have
demonstrated that some of these inflammatory mediators
(e.g., prostaglandins, bradykinin, leukotrienes, eosinophil
granule-derived cationic proteins, etc.) can markedly enhance
the sensitivity of TRPV1 and lower its threshold for activation
[16,71]. Furthermore, a recent report has further revealed a
higher tissue temperature in the airways of asthmatic patients
[65]. Thus, a given level of stimulation may evoke a greater
afferent discharge of the TRPV1-expressing C-fiber endings
and consequently a more severe bronchoconstriction via both
central cholinergic pathway and local axon reflex [16].
Exercise-induced asthma is a pathophysiological condition
of the airways induced by hyperventilation of dry air, and
present in approximately half of the asthmatic patients
[145,146]. It is generally believed that the primary cause of
bronchospasm during exercise is the injury of airway
epithelium caused by evaporation during hyperventilation,
resulting in the release of various inflammatory mediators
such as leukotrienes and histamine [145,146], which in turn
triggering bronchoconstriction. Recent studies have demon-
strated that TRPV4 is not only activated by hypotonicity as
described in the original observation [30], but also by a mild
increase in osmolarity, especially at the presence of tissue
inflammation [147,148]. However, whether activation of
TRPV4 channels expressed in the tracheobronchial epithelial
cells and subsequent Ca2+ influx are involved in triggering
the release of autacoids from epithelial and inflammatory
cells during exercise-induced asthma remains to be
determined.
4.3. Chronic Obstructive Pulmonary Disease (COPD)
COPD is an airway disease characterized by chronic
inflammation, and airflow obstruction that is usually progres-
sive, and not reversible; the disease state is often associated with
the presence of emphysema or chronic bronchitis. To our
knowledge, there is no existing evidence indicating a direct link
between TRP channels and the pathogenesis of COPD.
However, it is known that an increased production of certain
endogenous cytokines is involved in the chronic airway
inflammation and disease process of COPD [149,150], and
indirect evidence suggests that some of these pro-inflammatory
cytokines may lead to the stimulation of TRPV1-expressing
lung afferents. For example, tumor necrosis factor α and
interleukin 6 (IL-6) have been shown to sensitize the DRG
nociceptors and play a part in the inflammatory hyperalgesia
[151,152], and IL-1β can stimulate pulmonary C-fibers in rats
and rabbits [153,154]. Moreover, certain cytokines are known
to cause an increased release of prostaglandins [155], such as
PGE2, which can enhance the sensitivity of TRPV1 in
pulmonary sensory neurons [94]. Several types of the proteases
released from inflammatory cells such as mast cells andmacrophages during the chronic airway inflammation are also
known to modulate the TRPV1 sensitivity [44,124]. In addition,
activation of TRPV1 is known to evoke the release of
tachykinins from sensory endings in the airways, and these
neuropeptides can exert chemotactic action on certain immune
cells (e.g., mast cells and T-lymphocytes expressing neurokinin-
1 receptors), which in turn may induce inflammatory reaction
and contribute to the progressive deterioration of airway
structure and function [21,156].
4.4. Other airway diseases
4.4.1. Respiratory viral infection
Respiratory viral infections are often accompanied by
inflammation and injury of the airway mucosa that is densely
supplied by tachykinins-containing, TRPV1-expressing sensory
nerves [17,18]. Viral infection is also frequently associated with
more serious complications such as chronic cough and
exacerbation of asthma, especially in young children
[157,158]. Neurogenic inflammation in the airways evoked by
TRPV1 activation with capsaicin was amplified in rats
inoculated with respiratory syncytial virus (RSV), resulting
from the upregulation of neurokinin-1 (NK-1) receptors in the
airway epithelium and vascular epithelium [159]. Stimulation of
the TRPV1-expressing sensory nerves is also involved in the
overexpression of NK-1 receptors in CD4+ T cells and the
chemotactic effect on these lymphocytes during the RSV
infection in the airways [160]. Furthermore, inoculation of
guinea pigs or rats with RSV or Sendai virus (parainfluenza
virus) generates long-lasting airway inflammation, promotes
over-expression of NGF, and causes a phenotypic switch in
tachykininergic innervation of the airways [158,161,162].
Whether these observed increases in the airway tachykinin
synthesis and expression of NK-1 receptor are accompanied by
upregulation of TRPV1 expression in the viral infection-
induced airway hyperreactivity [163] is not known. More
importantly, whether respiratory viral infection alters the
excitability of TRPV1 in the airway sensory nerves also
remains to be determined.
4.4.2. Gastroesophageal reflux diseases
The association between gastroesophageal reflux and asthma
has been well documented in the literature; the prevalence of
gastroesophageal reflux symptoms in asthmatics is significantly
higher than that in the control population [164]. As described
earlier, TRPV1s are found in the unmyelinated sensory nerves
innervating the upper airways including larynx and trachea. The
pH in the gastric acid can be as low as 2.0; microaspiration of
gastric acid can activate these laryngeal and tracheobronchial
C-fibers, and elicits reflex bronchospasm via the cholinergic
efferent pathway and also evokes local release of tachykinins in
the airways. The latter can cause neurogenic inflammation,
mucus secretion, bronchospasm and cough. Furthermore, vagal
afferents innervating the esophagus can be also activated by
capsaicin and low pH [165], suggesting expression of TRPV1 in
these sensory nerves. Indeed, a recent study reported that
TRPV1-immunoreactive sensory fibers are expressed in human
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esophagitis [166]. Thus, exposure of the esophageal mucosa to
gastric acid may also cause bronchospasm by activating these
nociceptors and elicit vagal-mediated reflex and release of
substance P in the bronchial mucosa [164].
4.4.3. Irritant tracheobronchitis
Chronic exposure of the airways to chemical irritants,
occupational and environmental pollutants often leads to
development of irritant tracheobronchitis. For example, chronic
exposure to airborne particulate matter, such as fly ash and
smoke, is associated with respiratory disorders and increased
morbidity. TRPV1 channels are expressed in cultured human
airway epithelial cells, and particulate matter increases
intracellular Ca2+ that was inhibited by capsazepine in 70% of
the cells [167]. Particulate matter also induces epithelial
apoptosis via an action on the TRPV1 receptor. Accordingly,
inhibition of TRPV1 receptors has been suggested to be an
effective pharmacological intervention to prevent certain
pathological actions and toxicity induced by environmental
particulate matters [3,167]. In addition, prolonged exposure to
inhaled irritants or air pollutants such as ozone, toluene
disocyanate or cigarette smoke has also been shown to enhance
the sensitivity of airway sensory nerves to capsaicin as well as
the synthesis of TKs and CGRP [11,168,169].
5. Current status on drug discovery
Several synthetic antagonists of the TRPV1 channel have
been discovered and are under investigation mainly for
alleviating the pain sensation. Several phase-II clinical trials
on pain and migraine are currently in process. Airway diseases
such as asthma and chronic cough have been listed as an
potential indication for the TRPV1 antagonist drug discovery
research. For example, Merck, in collaboration with Neurogen
Corp, is developing an orally active TRPV1 antagonist, NGD-
8243 (MK-2295), for the treatment of pain, urinary incon-
tinence and asthma; a phase-II trial for pain began in November
2006. Glenmark Pharmaceutical Ltd also discovered a selective
TRPV1 antagonist, GRC-6210, for the treatment of pain,
urinary incontinence and asthma, and its phase-I clinical study
began in October 2006. However, to our knowledge, no TRPV1
antagonist compound has yet been tested for treatment of
airway diseases in humans.
6. Summary
Evidence obtained from electrophysiological and immuno-
histochemical studies has clearly demonstrated the expression
of TRPV channels in various cell types in the respiratory
tract. However, the roles of these cation channels in
regulating the overall respiratory function are still not clearly
understood. TRPV1 is abundantly expressed in the unmye-
linated sensory nerves innervating the airways and lung, and
widely recognized as a transducer as well as an integrator of
multiple physiological and environmental stimuli that the
airways are exposed to. Recent studies began to uncovermany of the endogenous substances that can either activate or
regulate the sensitivity of TRPV1, which further characterize
its important role in regulating the airway responsiveness,
especially under pathophysiological conditions. These new
findings further suggest the involvement of TRPV1 in the
pathogenesis of certain airway diseases such as asthma and
chronic cough, but definitive evidence has not yet been
established. The investigation in search for answers to these
questions is hindered by the unavailability of selective
antagonists to the individual TRPV receptors, other than
TRPV1. The development of TRPV-null mouse models have
offered excellent potential to answer some of these important
questions. More importantly, clinical studies designed to
block selectively the TRPV channels in the airways of the
patients with specific respiratory diseases are required to verify
the role of TRPVs in humans. If their involvements are
confirmed, TRPV channels could become important therapeutic
targets for developing novel treatments of these respiratory
diseases.
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